Soluble PD-1 Facilitates 4-1BBL–Triggered Antitumor Immunity against Murine H22 Hepatocarcinoma In vivo
Open Access
- 15 March 2007
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (6), 1823-1830
- https://doi.org/10.1158/1078-0432.ccr-06-2154
Abstract
Purpose: The use of costimulatory molecules targeting distinct T-cell signaling pathways has provided a means for triggering and enhancing antitumor immunity; however, it is still not fully understood what types of costimulatory molecules are suitable for the combination in tumor therapy. Our purpose in this study is to establish an effective antitumor immune approach by using costimulatory molecule 4-1BBL in combination with soluble PD-1.Keywords
This publication has 33 references indexed in Scilit:
- Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces AutoimmunityCancer Research, 2006
- 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccinesVaccine, 2006
- T-cell tolerance or function is determined by combinatorial costimulatory signalsThe EMBO Journal, 2006
- HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD‐1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanomaInternational Journal of Cancer, 2006
- Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv–expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusionMolecular Cancer Therapeutics, 2006
- The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinomaGene Therapy, 2005
- Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytesCancer Gene Therapy, 2005
- Dendritic-cell-based therapeutic vaccination against cancerCurrent Opinion in Immunology, 2005
- Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28− T cells and inhibit both T-Cell proliferation and CTL functionHuman Immunology, 2004
- Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T CellsCancer Biology & Therapy, 2003